Prototypical Stressors

Showing 826 to 850 of 871 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

719	2) Aluminum		None
6	2(3H)-Benzothiazolethione		None
101	2,6-dinitrotoluene	2,6-Dinitrotoluene, CAS-RN: 606-20-2, DTXSID5020528	None
264	2,6-dinitro-p-cresol		152: Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity
361	2,5-Hexanedione	2,5-Hexanedione, CAS-RN: 110-13-4, DTXSID8030138	None
348	2,4-Dithiobiuret	2,4-Dithiobiuret, CAS-RN: 541-53-7, DTXSID2034968	None
100	2,4-dinitrotoluene	2,4-Dinitrotoluene, CAS-RN: 121-14-2, DTXSID0020529	None
180	2,4-Dinitrophenol	2,4-Dinitrophenol, CAS-RN: 51-28-5, DTXSID0020523	263: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation
249	2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)		9 AOPs 21: Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 455: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development 456: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity 439: Activation of the AhR leading to metastatic breast cancer 458: AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals 459: AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals 494: AhR activation leading to liver fibrosis 563: Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis 578: AhR activation leading to cancer progression via immunosuppression
413	2,3-Pentanedione	2,3-Pentanedione, CAS-RN: 600-14-6, DTXSID6051435	None
414	2,3-Butanedione	2,3-Butanedione, CAS-RN: 431-03-8, DTXSID6021583	None
74	2,2',4,4'-Tetrahydroxybenzophenone	2,2',4,4'-Tetrahydroxybenzophenone, CAS-RN: 131-55-5, DTXSID5041306	2 AOPs 175: Thyroperoxidase inhibition leading to altered amphibian metamorphosis 152: Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity
845	2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether	2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether, CAS-RN: 1163-19-5, DTXSID9020376	None
512	2-Methoxyestradiol	2-Methoxyestradiol, CAS-RN: 362-07-2, DTXSID3040938	None
7	2-mercaptobenzothiazole	2-Mercaptobenzothiazole, CAS-RN: 149-30-4, DTXSID1020807	None
168	2-Imidazolidinimine, 1-[(6-chloro-3-pyridinyl)methyl]-N-nitro-, (2E)-		None
236	2-Chlorobenzalmalononitrile		196: Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation
102	2-amino-4,6-dinitrotoluene	2-Amino-4,6-dinitrotoluene, CAS-RN: 35572-78-2, DTXSID6044068	None
867	2-Amino-1-methyl-6-phenylimidazo [4,5-b]pyridine	2-Amino-1-methyl-6-phenylimidazo [4,5-b]pyridine, CAS-RN: 105650-23-5, DTXSID3037628	644: Bulky DNA adducts leading to chromosomal aberrations and mutations
5	17beta-Trenbolone	17beta-Trenbolone, CAS-RN: 10161-33-8, DTXSID0034192	3 AOPs 23: Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) 376: Androgen receptor agonism leading to male-biased sex ratio 496: Androgen receptor agonism leading to reproduction dysfunction （in zebrafish）
4	17beta-Estradiol	17beta-Estradiol, CAS-RN: 50-28-2, DTXSID0020573	3 AOPs 314: Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) 503: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation 504: SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level
85	169590-42-5		None
73	131-55-5		None
640	11-Keto-testosterone	11-Ketotestosterone, CAS-RN: 564-35-2, DTXSID8036499	376: Androgen receptor agonism leading to male-biased sex ratio
372	10238-21-8		None